Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs

Human Gene Therapy Clinical Development

Volumn 24, Issue 4, 2013, Pages 174-181

  Leblanc, Amy K ^a,b   Naik, Shruthi ^c   Galyon, Gina D ^a   Jenks, Nathan ^c   Steele, Mike ^c   Peng, Kah Whye ^c   Federspiel, Mark J ^c   Donnell, Robert ^a   Russell, Stephen J ^c  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BETA INTERFERON; ENDOTOXIN; ONCOLYTIC VIRUS; SODIUM IODIDE SYMPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BEAGLE; CONTROLLED STUDY; DERMATITIS; DISSEMINATED CANCER; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUTHANASIA; FEVER; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNE RESPONSE; LEUKOCYTE COUNT; LIMIT OF DETECTION; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NONHUMAN; ONCOLYTIC VIROTHERAPY; ORAL MUCOSAL DISEASE; PARTIAL THROMBOPLASTIN TIME; PERSISTENT VIRUS INFECTION; PETECHIA; PRIORITY JOURNAL; PROTHROMBIN TIME; SCROTAL DERMATITIS; SCROTUM; SHOCK; THROMBOCYTE COUNT; URINARY TRACT INFECTION; VESICULAR STOMATITIS VIRUS; VIRAL GENE THERAPY; VIREMIA; VIRUS GENE; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS SHEDDING;

ANIMALS; DNA, RECOMBINANT; DOGS; GENETIC VECTORS; INJECTIONS, INTRAVENOUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; ORGAN SPECIFICITY; VESICULOVIRUS;

EID: 84907247400     PISSN: 23248637     EISSN: 23248645     Source Type: Journal    
DOI: 10.1089/humc.2013.165     Document Type: Article

References (17)

1. Barber, G.N. (2004). Vesicular stomatitis virus as an oncolytic vector. Viral Immunol. 17, 516-527. (Pubitemid 40054231)
2. Flatland, B., Fry, M.M., Leblanc, C.J., and Rohrbach, B.W. (2010). Leukocyte and platelet changes following low-dose lipopoly-saccharide administration in five dogs. Res. Vet. Sci. 90, 89-94.
3. Jenks, N., Myers, R., Greiner, S.M., et al. (2009). Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum. Gene Ther. 21, 451-462.
4. Kowalczyk, T., and Brandly, C.A. (1954). Experimental infection of dogs, ferrets, chinchillas and hamsters with vesicular stomatitis virus. Am. J. Vet. Res. 15, 98-101.
5. Lieber, A., He, C.Y., Meuse, L., et al. (1997). The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71, 8798-8807. (Pubitemid 27446464)
6. Muruve, D.A., Barnes, M.J., Stillman, I.E., and Libermann, T.A. (1999). Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10, 965-976. (Pubitemid 29195426)
7. Naik, S., and Russell, S.J. (2009). Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin. Biol. Ther. 9, 1163-1176.
8. Naik, S., Nace, R., Barber, G.N., and Russell, S.J. (2012a). Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta. Cancer Gene Ther. 19, 443-450.
9. Naik, S., Nace, R., Federspiel, M.J., et al. (2012b). Curative one-shot systemic virotherapy in murine myeloma. Leukemia 26, 1870-1878.
10. Nielsen, L.N., Wiinberg, B., Kjelgaard-Hansen, M., and Kris-tensen, A.T. (2011). The presence of antiphospholipid antibodies in healthy Bernese Mountain Dogs. J. Vet. Intern. Med. 25, 1258-1263.
11. Obuchi, M., Fernandez, M., and Barber, G.N. (2003). Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77, 8843-8856. (Pubitemid 36936096)
12. Paoloni, M.C., and Khanna, C. (2007). Comparative oncology today. Vet. Clin. North Am. Small Anim. Pract. 37, 1023-1032. (Pubitemid 47578468)
13. Roberts, A., Buonocore, L., Price, R., et al. (1999). Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73, 3723-3732. (Pubitemid 29189814)
14. Russell, S.J., and Peng, K.W. (2007). Viruses as anticancer drugs. Trends Pharmacol. Sci. 28, 326-333. (Pubitemid 47016683)
15. Salmon, P., Le Cotonnec, J.Y., Galazka, A., et al. (1996). Phar-macokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J. Interferon Cy-tokine Res. 16, 759-764. (Pubitemid 26389112)
16. Shayakhmetov, D.M., Li, Z.Y., Ni, S., and Lieber, A. (2004). Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol. 78, 5368-5381. (Pubitemid 38581487)
17. Triplett, D.A. (1998). Many faces of lupus anticoagulants. Lupus 7 Suppl. 2, S18-S22. (Pubitemid 28484574)